+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of Surovatamig AZD0486 and rituximab for treating participants with previously untreated follicular lymphoma. This global, randomized, open-label Phase III study aims to compare the efficacy, safety, and added benefit of this combination versus three standard immunochemotherapy regimens chosen by the investigator. The study includes a safety run-in phase to determine the recommended dose followed by the main Phase III comparison. The study has two parts first, a safety run-in to compare different dose levels of Surovatamig combined with rituximab to establish the recommended Phase III dose RP3D. Then, the Phase III part, which compares three treatment arms two with different Surovatamig plus rituximab schedules and one with investigators choice of standard chemoimmunotherapy regimens R-CVP, R-CHOP, or B-R followed by rituximab maintenance. Participants are randomly assigned to one of these arms. During the study, participants undergo safety monitoring, including tracking of adverse events and treatment tolerability, for up to 10 years. Researchers assess treatment response, progression, and survival outcomes over this period. Participants receive regular evaluations of disease status, organ function, and overall health. The study aims to measure safety, the best dose, and whether Surovatamig plus rituximab is superior to standard treatments in this patient group.

Age: 18Years - 130YearsAll GendersPhase 3
244 locations
P

Actively Recruiting

Researchers are evaluating ziftomenib, a drug targeting the menin pathway, for treating adults with acute myeloid leukemia AML who have specific genetic mutations. This research involves two parallel phase 3 studies comparing ziftomenib combined with standard therapies against placebo plus standard therapies in patients who have not yet received AML treatment. The studies focus on patients with nucleophosmin 1 mutation NPM1-m or lysine-specific methyltransferase 2A rearranged KMT2A-r AML. In the Nonintensive Therapy Study, older or medically unfit patients receive either ziftomenib or placebo alongside venetoclax and azacitidine. In the Intensive Therapy Study, medically fit patients are randomized to receive ziftomenib or placebo combined with cytarabine and daunorubicin during induction, cytarabine plus ziftomenib or placebo during consolidation, and ziftomenib or placebo alone during maintenance. Both studies use a double-blind design where neither patients nor physicians know the treatment assignments. Participants will be monitored for up to 36 months after enrollment, with evaluations including overall survival, event-free survival, complete remission rates, and measurable residual disease in bone marrow. Safety and tolerability will be assessed through adverse event reports and drug concentration measurements. Patient-reported outcomes related to health will also be collected. The total study duration extends up to November 2031, allowing long-term follow-up and assessment of treatment effects.

Age: 18Years +All GendersPhase 3
136 locations